Migraine is a common neurological disorder that causes severe pain on one or both sides of the head, including nausea, vomiting, and sensitivity to light, sounds, or smells. In practice, migraine is often treated initially with analgesics such as ibuprofen, diclofenac, and triptans, as well as antiemetics as adjunctive therapy. However, few specific drugs have been approved for the preventive treatment of migraine, so off-label drug use (OLDUs) are often used in this field, such as β blockers (commonly used to lower blood pressure), anticonvulsants (such as topiramate or sodium valproate), antidepressants (such as amitriptyline), and botulinum toxin type A. According to the Guidelines for the Prevention and Treatment of Migraine in China (2022), nonsteroidal anti-inflammatory drugs (NSAIDs) and triptans are the main acute treatment drugs for migraine in China.

From January to February of this year, the oil processing industry, black metal smelting and pressure-proof industries of petroleum coal and other fuel processing have changed from profit to losses. It is worth noting that the profit of chemical raw materials and chemical products manufacturing from January to February decreased by 56.6%, a large decrease. my country's chemical raw materials and chemical products manufacturing profits and factory prices have declined. According to data released by the National Bureau of Statistics on March 9, in February 2023, the factory price of industrial producers in the country decreased by 1.4%year -on -year, which was the same as the month -on -month. Among them, the export price of chemical raw materials and chemical manufacturing manufacturing industries decreased by 6%year -on -year. The profit of my country's chemical raw materials and chemical products manufacturing industry has shifted from positive and negative since October last year, and continued to increase after entering 2023.

As the "vane" of the global dyeing industry, after 22 years of cultivation of China's international dye industry, organic pigments, and textile chemicals exhibitions, it has now become an influential professional exhibition in the world. The exhibition is the first dye exhibition to obtain the UFI certification of the International Expo Alliance. It has been rated as the high -quality convention and exhibition project in China and the Shanghai Excellent Exhibition. It has become a must -have for dynasties in the dye industry each year. In general, in the first quarter, with the rapid prevention and control of the epidemic in my country, the stable growth and stability of employment and stable price policy measures were giving up, and positive factors accumulated increased. Looking forward to the second quarter, mild recovery will still be the main trend, but the recovery process will be affected by multiple factors.

The 23rd China International Exhibition on Agrochemicals and Plant Protection (CAC2023) was grandly opened at the National Exhibition and Convention Center (Shanghai) on May 23, 2023! The 13th China International New Fertilizer Exhibition (FSHOW2023) and the 23rd China International Agrochemical Equipment and Plant Protection Equipment Exhibition were also held at the same time! After two years, CAC2023 is brilliantly presented. The exhibition site was very popular, the enthusiasm of agrochemical colleagues was high, and tens of thousands of people gathered in the world of agrochemistry to jointly promote the development of world agrochemistry.

With the disclosure of each pharmaceutical company's 2022 results, we collated the R&D expenses of 20 pharmaceutical companies: Baekje Shenzhou (11.2 billion yuan), Hengrui Pharmaceutical (4.9 billion yuan), China Biopharma (4.5 billion yuan) ranked in the top three, Baekje Shenzhou is still sitting firmly in the "R & D first" position. Throughout the recent years, the domestic pharmaceutical enterprises R & D investment ranking, it is easy to see that the top 10 enterprises basically remain unchanged, R & D innovation strength of enterprises highly focused, the formation of the strongest situation. With the resonance of policy, technology, capital and talent, China's innovative drugs will have a booming decade. 2022, the total R&D investment of the top 10 pharmaceutical companies in the world will be US$104.32 billion (RMB 722.2 billion), while the cumulative R&D investment of the top 10 pharmaceutical companies in China is only RMB 41.7 billion, a 17 times gap compared to the world.